Analystreport

Halozyme Therapeutics (NASDAQ:HALO) was downgraded by analysts at Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.

Halozyme Therapeutics, Inc.  (HALO) 
Last halozyme therapeutics, inc. earnings: 2/24 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: halozyme.com/investors/default.aspx